MX2024003132A - Metodos para tratar la hematopoyesis clonal de potencial indeterminado (chip) con inhibidores del antigeno linfocitario 75 (ly75), grupo de diferenciacion 164 (cd164) o poli (adp-ribosa) polimerasa 1 (parp1). - Google Patents
Metodos para tratar la hematopoyesis clonal de potencial indeterminado (chip) con inhibidores del antigeno linfocitario 75 (ly75), grupo de diferenciacion 164 (cd164) o poli (adp-ribosa) polimerasa 1 (parp1).Info
- Publication number
- MX2024003132A MX2024003132A MX2024003132A MX2024003132A MX2024003132A MX 2024003132 A MX2024003132 A MX 2024003132A MX 2024003132 A MX2024003132 A MX 2024003132A MX 2024003132 A MX2024003132 A MX 2024003132A MX 2024003132 A MX2024003132 A MX 2024003132A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- chip
- parp1
- adp
- ribose
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163243564P | 2021-09-13 | 2021-09-13 | |
| US202163271171P | 2021-10-24 | 2021-10-24 | |
| PCT/US2022/076298 WO2023039580A2 (en) | 2021-09-13 | 2022-09-12 | Methods of treating clonal hematopoiesis of indeterminate potential (chip) with lymphocyte antigen 75 (ly75), cluster of differentiation 164 (cd164), or poly(adp-ribose) polymerase 1 (parp1) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024003132A true MX2024003132A (es) | 2024-04-10 |
Family
ID=83598663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024003132A MX2024003132A (es) | 2021-09-13 | 2022-09-12 | Metodos para tratar la hematopoyesis clonal de potencial indeterminado (chip) con inhibidores del antigeno linfocitario 75 (ly75), grupo de diferenciacion 164 (cd164) o poli (adp-ribosa) polimerasa 1 (parp1). |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230113866A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4401831A2 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024533459A (cg-RX-API-DMAC10.html) |
| CA (1) | CA3229899A1 (cg-RX-API-DMAC10.html) |
| MX (1) | MX2024003132A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023039580A2 (cg-RX-API-DMAC10.html) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002953223A0 (en) * | 2002-12-06 | 2003-01-02 | The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland | Novel therapeutic molecules and uses thereof |
| WO2014011465A2 (en) * | 2012-07-13 | 2014-01-16 | Albert Einstein College Of Medicine Of Yeshiva University | Aptamer-targeted antigen delivery |
| GB201220010D0 (en) * | 2012-11-07 | 2012-12-19 | Oxford Biotherapeutics Ltd | Therapeutic amd diagnostic target |
| EP3426804A4 (en) * | 2016-03-11 | 2020-03-25 | The Brigham and Women's Hospital, Inc. | COMPOSITIONS AND METHODS FOR TREATING CHEMOTHERAPY RESISTANT CANCER |
| GB201703876D0 (en) * | 2017-03-10 | 2017-04-26 | Berlin-Chemie Ag | Pharmaceutical combinations |
| ES3040741T3 (en) * | 2020-02-24 | 2025-11-04 | Univ Leland Stanford Junior | Methods of analyzing cell free nucleic acids and applications thereof |
-
2022
- 2022-09-12 JP JP2024515871A patent/JP2024533459A/ja active Pending
- 2022-09-12 CA CA3229899A patent/CA3229899A1/en active Pending
- 2022-09-12 WO PCT/US2022/076298 patent/WO2023039580A2/en not_active Ceased
- 2022-09-12 US US17/931,396 patent/US20230113866A1/en active Pending
- 2022-09-12 MX MX2024003132A patent/MX2024003132A/es unknown
- 2022-09-12 EP EP22786243.0A patent/EP4401831A2/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023039580A2 (en) | 2023-03-16 |
| WO2023039580A3 (en) | 2023-06-08 |
| JP2024533459A (ja) | 2024-09-12 |
| CA3229899A1 (en) | 2023-03-16 |
| EP4401831A2 (en) | 2024-07-24 |
| US20230113866A1 (en) | 2023-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rashidi et al. | Gut dysbiosis during antileukemia chemotherapy versus allogeneic hematopoietic cell transplantation | |
| Wang et al. | Circulating activated lymphocyte subsets as potential blood biomarkers of cancer progression | |
| Rytwinski et al. | Screening for social anxiety disorder with the self‐report version of the Liebowitz Social Anxiety Scale | |
| Billhult et al. | Strength of motherhood: nonrecurrent breast cancer as experienced by mothers with dependent children | |
| Mukhtar et al. | Survival predictors of Burkitt's lymphoma in children, adults and elderly in the United States during 2000–2013 | |
| Matarazzo et al. | Predictive validity of the Columbia‐suicide severity rating scale among a cohort of at‐risk veterans | |
| Dhuffar et al. | Barriers to female sex addiction treatment in the UK | |
| Kim et al. | Gendered and racialized social expectations, barriers, and delayed breast cancer diagnosis | |
| SG171599A1 (en) | Blood group antigens of different types for diagnostic and therapeutic applications | |
| Schilder et al. | The impact of different definitions and reference groups on the prevalence of cognitive impairment: a study in postmenopausal breast cancer patients before the start of adjuvant systemic therapy | |
| Huemer et al. | AID induces intraclonal diversity and genomic damage in CD86+ chronic lymphocytic leukemia cells | |
| WO2023039580A3 (en) | Methods of treating clonal hematopoiesis of indeterminate potential (chip) with lymphocyte antigen 75 (ly75), cluster of differentiation 164 (cd164), or poly(adp-ribose) polymerase 1 (parp1) inhibitors | |
| Rasmussen et al. | High numbers of clonal CD19+ cells in the peripheral blood of a patient with multiple myeloma | |
| Anderson et al. | A task analysis of client re‐engagement: Therapeutic de‐escalation of high‐conflict coparents | |
| Hamada et al. | Estimation and comparison of cumulative incidences of biliary self‐expandable metallic stent dysfunction accounting for competing risks | |
| Zhang et al. | Night shift work and sleep experiences in older night shift nurses | |
| Alhothali et al. | Rising burden of enterococcal bacteremia in Victoria, Australia: population-based incidence and antimicrobial resistance trends from three decades of surveillance | |
| Chan et al. | A comparative study of the experiences of a group of Hong Kong Chinese and Australian women diagnosed with postnatal depression | |
| Cañigueral et al. | Don't Look at Me, I'm Wearing an Eyetracker! | |
| Park et al. | What is the sensitive period to initiate auditory stimulation for the second ear in sequential cochlear implantation? | |
| Xu et al. | Unusual T‐lymphoblastic blast phase of chronic myelogenous leukemia | |
| HK40113495A (en) | Methods of treating clonal hematopoiesis of indeterminate potential (chip) with lymphocyte antigen 75 (ly75), cluster of differentiation 164 (cd164), or poly(adp-ribose) polymerase 1 (parp1) inhibitors | |
| Lam et al. | Value of flow cytometric analysis of peripheral blood samples in children diagnosed with acute lymphoblastic leukemia | |
| Mahmutović et al. | The importance of social support for elderly people | |
| MX2024005298A (es) | Asociacion de la proteina 1a de leucemia/linfoma de linfocitos t (tcl1a) con hematopoyesis clonal de potencial indeterminado (chip). |